Europe Point of Care (PoC) Diagnostics Market Size, Share, Trends, & Industry Analysis Report
By Product (Glucose Testing, Hb1Ac Testing, Coagulation), By Mode of Prescription, By End Use – Market Forecast, 2025–2034
- Published Date:Oct-2025
- Pages: 128
- Format: PDF
- Report ID: PM6439
- Base Year: 2024
- Historical Data: 2020-2023
Overview
The Europe point of care (PoC) diagnostics market size was valued at USD 9.28 billion in 2024, growing at a CAGR of 3.92% from 2025–2034. Key factors driving demand include rising shift towards self-testing, supportive government policies and healthcare investment, rise in geriatric population and increasing need for chronic disease management, and rising advances in PoC technologies.
Key Insights
- In 2024, infectious diseases held the largest share at 57.65%, boosted by increasing cases and the need for rapid and accurate diagnostic solutions to control outbreaks.
- The over-the-counter segment is expected to grow faster, driven by a clear consumer shift to home-based healthcare and the proliferation of self-monitoring approaches.
- Clinics accounted for a 36.97% share in 2024, providing consumers with an ideal solution due to the increasing demand for fast, reliable, and affordable outpatient diagnostic services.
- The Germany PoC diagnostics market accounted for 17.91% revenue share in 2024 driven by increasing adoption of diagnostic technologies and rising healthcare infrastructure.
- The UK is expected to be the fastest growing market, driven by increasing interest in home-testing solutions additionally, the wider transition to decentralized healthcare.
Industry Dynamics
- Europe's increasing elderly population is prone to chronic diseases, such as diabetes, requiring regular monitoring, further increasing demand for point-of-care diagnostics.
- Technological advances are making PoC devices more user-friendly and facilitating their incorporation.
- The new EU IVDR regulation creates very expensive and difficult barriers to better access and compliance with the new regulations.
- The rising need for rapid AMR testing at the PoC represents a major driver for innovation and revenue expansion.
Market Statistics
- 2024 Market Size: USD 9.28 billion
- 2034 Projected Market Size: USD 13.61 billion
- CAGR (2025-2034): 3.92%
- Germany: Significant Market Share in 2024
AI Impact on Europe Point of Care (PoC) Diagnostics Market
- AI algorithms analyze complex data to improve the precision of test results, reducing human error and supporting more reliable diagnoses at the point of care.
- AI accelerates analysis, delivering critical insights in minutes rather than hours and enabling immediate clinical decision-making, by automating data interpretation.
- AI identify patterns and trends, enabling early detection of outbreaks or antimicrobial resistance and transforming PoC devices into proactive health tools.
Point of care (PoC) diagnostics are medical tests performed at or near the patient’s location, rather than in a laboratory for timely and accurate diagnostic results. The market in Europe is driven by the rising shift towards self-testing as the patients are increasingly in need for timely diagnostic, accessible, and convenient options which help them with regular monitoring of health. This shift is further supported by the rising demand for self-based testing kits, which helps in reducing the burden on healthcare providers, reducing waiting time for reports, and provide autonomy to the consumers. Self-based tests focus on early detection of disease, by providing diagnostics closer to the patients reach, highlighting the regular support to the patients.
-diagnostics-market-size,-by-country-2020---2034.webp)
The Europe PoC diagnostics market is further driven by the supportive government policies. European government policies are promoting initiatives to support faster diagnostics to improve patient outcomes, and boost healthcare infrastructure. For instance, in March 2025, the EU4Health stated that the EU is aiming for the development of rapid, less than one hour PoC testing devices for antimicrobial testing and for the identification of bacterial or fungal disease causing infections.
Moreover, rising funding initiatives, supportive reimbursement policies and frameworks that support integrating the innovative technologies into routine monitoring have boosted the adoption of the PoC diagnostics. According to a July 2023 report from the European Union, HERA invest granted approximately USD 106 million under the InvestEU program. This funding supports the development and scaling of refined solutions such as medicinal products, diagnostic, medical device, and others, highlighting the government role in supporting the PoC testing in Europe.
Drivers & Opportunities
Growing Geriatric Population and Chronic Disease Management: The rise in geriatric population and increasing need for chronic disease management is boosting the PoC diagnostics market in Europe. Aging people are more prone to the conditions such as diabetes, cardiovascular diseases, and respiratory problems, which requires regular and timely monitoring. According to a January 2024 European Union data, 21.6% that is one fifth of Europe’s population was aged 65 years and over, stating the rising need for reliable PoC devices for timely monitoring. PoC diagnostic allow for better management of disease which consequently reduce the dependency of hospital testing and visits. This is particularly evident in the management of long term chronic conditions where continuous monitoring and quick decision making is crucial. A July 2025, European Union data stated that more than 35.3% that is one third of the Europe population had a long standing chronic problem in 2024. Therefore, by addressing the needs of aging population PoC diagnostic are improving the quality and reducing the pressure on healthcare environments.
Rising Advancement and Innovation in PoC Technology: Rising advances in PoC technologies such as integration of novel sensor, digital health platforms, miniaturization, and other advancements support the rising demand for PoC diagnostics and making it user-friendly. For example, in May 2025, Neoul launched miLab BCM an AI-powered PoC device that integrate blood morphology analysis and complete blood count (CBC) to deliver rapid diagnostic results from a blood sample into an automated system. These innovations expand the area of conditions that can be monitored and are accessible across healthcare environments. Furthermore, the integration of data sharing capabilities and connectivity features also supports the remote monitoring and patient focused care. Therefore, by offering technological driven, faster and precise solutions are boosting the growth opportunities for the PoC diagnostics.
-diagnostics-market-size-worth-usd-13.61-billion-by-2034.webp)
Segmental Insights
Product Analysis
Based on product, the segmentation includes glucose testing, Hb1Ac testing, coagulation, fertility, infectious diseases, cardiac markers, thyroid stimulating hormone, hematology, primary care systems, decentralized clinical chemistry, feces, lipid testing, cancer marker, blood gas/electrolytes, ambulatory chemistry, drug abuse testing, and urinalysis. The infectious diseases segment accounted for 57.65% revenue share in 2024 driven by the increasing infectious disease case and the need for accurate, rapid, and accessible solution to control the spread of disease. The PoC diagnostic offers rapid results for early detection and timely treatment decisions which makes them a preferred option for consumers as well as healthcare providers. Moreover, the rising focus on the demand for efficient diagnostics method integrated with preventive care has further supported the expansion of the PoC diagnostics.
Mode of Prescription Analysis
In terms of mode of prescription, the segmentation includes OTC and prescription-based. The prescription-based segment dominated the market with USD 6.33 billion revenue share in 2024 driven by the need for physician testing for complex and high risk conditions. The prescription-based diagnostics provide greater accuracy, following of clinical protocols, and proper understanding of results by professionals which are essential in chronic disease management and hospital based environments. Furthermore, the involvement of professional also build trust and promote wider adoption of if these tests in clinical settings. Therefore, prescription-based diagnostics support quality and safety in medical testing.
The OTC segment is expected to witness significant growth at a CAGR of 1.9% during the forecast period due to the rising shift towards home-based healthcare, and self-monitoring. The rising focus on personal health management, increasing consumer awareness, and availability of user-friendly diagnostic kits are boosting the expansion of OTC. The OTC PoC diagnostics provide individuals privacy, autonomy, and convenience in managing their health for conditions such as infectious disease, glucose monitoring, and other diseases. Thus, the broader shift towards patient-centric and preventive care contributes to the expansion opportunities.
End Use Analysis
Based on end use, the segmentation includes, clinics, hospitals, home, assisted living healthcare facilities, and laboratory. The clinics segment held 36.97% share of the market in 2024 due to the increasing demand for cost effective, fast and reliable diagnostic services which is offered in outpatient and patient care environments. Clinics are the crucial access points for patients who are in need for immediate and rapid testing without the need for hospital visit, improving care delivery and reducing waiting time. Furthermore, clinics have the ability to integrate PoC diagnostics to support timely intervention, enhance routine practice efficiency, and manage patient satisfaction. Therefore, clinics hold a major role in shaping the utilization and growth of PoC diagnostics.
-diagnostics-market-by-product-analysis,-2020---2034.webp)
Country Analysis
Germany Point of Care (PoC) Diagnostics Market
The Germany PoC diagnostics market accounted for 17.91% revenue share in 2024 driven by increasing adoption of diagnostic technologies and rising healthcare infrastructure. Europe has a high focus on efficiency and precision in healthcare delivery, which has boosted the demand for rapid testing solutions in hospitals, clinics, and home-based monitoring. According to a November 2024 European Union report, Germany accounted for 12.6% of current healthcare expenditure that is the highest amongst all countries in Europe. The growing awareness on chronic disease and healthcare management further contributes to the PoC diagnostics. Moreover, the rising innovation in testing platform and integration into the clinical workflows improve both patient outcomes and accessibility, supporting the Germany market growth.
UK Point of Care (PoC) Diagnostics Market
The UK market is expected to witness fastest growth at a CAGR of 2.5% during the forecast period attributed to the increasing demand for adoption of home-based testing solutions and decentralized healthcare settings. The UK healthcare system focus on early intervention of disease and patient centric solutions which is driving the reliance on rapid diagnostic tools and provide immediate test results. Moreover, strong focus on integration of digital health with growing consumer acceptance of self-testing is also contributing to the expansion of UK market. Therefore, as healthcare delivery in the UK continue to evolve, PoC diagnostics is expected to witness significant growth in the country.
-diagnostics-market-country-insights,-2020-–-2034.webp)
Key Players & Competitive Analysis Report
The European PoC diagnostics landscape is influenced by competitive intelligence and strategy involving expense by small to medium businesses. Vendor strategies will take account of significant investment into new technology, credits to AI, to drive revenue stream sustainability forward. There will also be disruptions and trends that indicate substantial and encouraging expansion opportunities building off a drive for rapid antimicrobial resistance testing. The experts' perspectives suggest business models will continue their evolution, and navigation of technology, regulatory and climate change will be critical to competitive positioning and unlocking any potential latent demand and opportunities both across and within developed and emerging market segments.
Major companies operating in the Europe point of care (PoC) diagnostics industry include bioMérieux; Boditech Med Inc.; EKF Diagnostics; Grifols; HORIBA, Ltd.; Nova Biomedical; Qiagen; Roche Diagnostics; Siemens Healthineers; and Werfen.
Key Players
- bioMérieux
- Boditech Med Inc.
- EKF Diagnostics
- Grifols
- HORIBA Medical / HORIBA ABX SAS
- Nova Biomedical / Nova Biomedical EMEA
- Qiagen
- Roche Diagnostics
- Siemens Healthineers
- Werfen
Industry Developments
- April 2025: Boditech Med launched new infectious disease PoC platforms targeting sepsis, AMR, tuberculosis, and GI health. It included the rapid AFIAS IGRA-TB test and AFIAS MxA/CRP for infection differentiation.
- June 2023: Sysmex launched a testing system in Europe for rapid UTI diagnosis and antimicrobial susceptibility testing from urine samples, delivering AST results in approximately 30 minutes to combat antimicrobial resistance.
Europe Point of Care (PoC) Diagnostics Market Segmentation
By Product Outlook (Revenue, USD Billion, 2020–2034)
- Glucose Testing
- Hb1Ac Testing
- Coagulation
- Fertility
- Infectious Diseases
- HIV
- Clostridium Difficile
- HBV
- Pneumonia or Streptococcus Associated Infections
- Respiratory Syncytial Virus (RSV)
- HPV
- Influenza/Flu
- HCV
- MRSA
- TB and Drug-Resistant TB
- HSV
- Others
- Cardiac Markers
- Thyroid Stimulating Hormone
- Hematology
- Primary Care Systems
- Decentralized Clinical Chemistry
- Feces
- Lipid Testing
- Cancer Marker
- Blood Gas/Electrolytes
- Ambulatory Chemistry
- Drug Abuse Testing
- Urinalysis
By Mode of Prescription (Revenue, USD Billion, 2020–2034)
- OTC
- Prescription-based
By End Use Outlook (Revenue, USD Billion, 2020–2034)
- Clinics
- Physician Office
- Pharmacy & Retail Clinics
- Non-practice Clinics
- Urgent Care Clinic
- Hospitals
- Home
- Assisted Living Healthcare Facilities
- Laboratory
By Country Outlook (Revenue, USD Billion, 2020–2034)
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
Europe Point of Care (PoC) Diagnostics Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 9.28 Billion |
|
Market Size in 2025 |
USD 9.63 Billion |
|
Revenue Forecast by 2034 |
USD 13.61 Billion |
|
CAGR |
3.92% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
|
Segments Covered |
|
|
Country Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The market size was valued at USD 9.28 billion in 2024 and is projected to grow to USD 13.61 billion by 2034.
The market is projected to register a CAGR of 3.92% during the forecast period.
The Germany PoC diagnostics market accounted for 17.91% revenue share in 2024.
A few of the key players in the market are include bioMérieux; Boditech Med Inc.; EKF Diagnostics; Grifols; HORIBA, Ltd.; Nova Biomedical; Qiagen; Roche Diagnostics; Siemens Healthineers; and Werfen.
The infectious diseases segment accounted for 57.65% revenue share in 2024.
The prescription-based segment dominated the market with USD 6.33 billion revenue share in 2024.
© 2025 Polaris Market Research and Consulting. All rights reserved
